Stellaromics Makes Strides with Pyxa® Instrumentation at Top Research Institutes in the U.S. and Europe

Overview of Stellaromics' New Adoption

Stellaromics, Inc., renowned for its pioneering work in 3D spatial multi-omics, has achieved a significant milestone with the initial commercial deployment of its innovative Pyxa® platform. This cutting-edge technology represents the first solution capable of delivering authentic 3D spatial multi-omics in intact tissue samples and is set to revolutionize the field of biological research. The collaborative institutions receiving these advanced instruments include the Icahn School of Medicine at Mount Sinai in New York City, CNAG in Barcelona, the Karolinska Institutet in Stockholm, and Stanford University in California.

Significance of Pyxa®

The introduction of Pyxa® marks a notable shift in how researchers can examine subcellular details across tissue sections measuring up to 100 micrometers in thickness. This breakthrough allows scientists to better visualize tissue architecture, unravel intricate cell–cell interactions, and observe molecular gradients that often remain obscured in conventional thin-section methodologies.

"Each of these laboratories embodies the forward-thinking science Pyxa was originally designed for," remarked Dr. Todd Dickinson, CEO of Stellaromics. The institutions are recognized for their efforts in expanding the frontiers of tissue resolution and have acknowledged the limitations posed by flat 2D tissue analyses. The implementation of Pyxa® is a step towards addressing these challenges across various research domains including neuroscience, oncology, and immunology.

Details About Participant Institutions

1. Icahn School of Medicine at Mount Sinai (New York, NY): Led by Professor Robert Sebra, the team here leverages multi-omomic techniques to explore the cellular niches that contribute to disease states. Dr. Sebra emphasizes the significance of understanding spatial relationships between cells in deciphering pathogenic versus normal cellular functions.

2. CNAG (Centro Nacional de Análisis Genómico, Barcelona, Spain): Under Dr. Anna Pascual-Reguant's guidance, the Spatial Genomics Team aims to unravel how tissue structures and gene expression patterns dictate immune reactions in diseases such as cancer and chronic inflammation. The incorporation of 3D spatial transcriptomics will enhance their understanding of cellular organization within various niches.

3. Karolinska Institutet (Stockholm, Sweden): The Developmental Neurogenomics group, directed by Dr. Michael Ratz, is pioneering the use of Pyxa® to investigate brain development through next-generation techniques that integrate spatial and single-cell transcriptomics.

4. Stanford University (Stanford, CA): The laboratory of Dr. Karl Deisseroth is known for its groundbreaking work in optogenetics and hydrogel-tissue chemistry, methods that will significantly benefit from the volumetric data provided by Pyxa®.

Future Prospects

The introduction of Pyxa® at such prominent research facilities underscores Stellaromics' commitment to advancing 3D spatial biology. Veronica Mankinen, Senior Vice President of Global Commercial Operations, stated, "These placements at top-tier institutions serve to validate both our technology and our capacity to provide global support. We are on track to expand Pyxa's availability across North America, Europe, and the Asia-Pacific region through 2026."

In addition, early data from ongoing projects in oncology and neuroscience illustrate the advantages of volumetric spatial analysis, demonstrating how this contemporary approach opens new avenues for scientific exploration. Researchers anticipate displaying Pyxa-generated data at forthcoming gatherings, including the European Society for Spatial Biology (ESSB) meeting and the Society for Neuroscience's (SfN) Neuroscience 2026 annual meeting.

Conclusion

Stellaromics is on a notable trajectory toward transforming 3D spatial multi-omics research with Pyxa®. The deployment of this platform across elite institutions is set to not only advance scientific understanding but also ultimately improve health outcomes and precision medicine. With continuous enhancements and new applications lined up for the future, the potential for significant breakthroughs in the realms of biology and medicine is promising as Stellaromics leads the charge into a new era of research capabilities.